Winton Group’s Cardlytics CDLX Stock Holding History

Winton Group’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-327	Closed	-$467K	–	1377
2020 Q4	$467K	Buy	+327	New	+$349K	0.03%	827
2019 Q4	–	Sell	-870	Closed	-$292K	–	1569
2019 Q3	$292K	Buy	+870	New	+$279K	﹤0.01%	1283

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Winton Group's CDLX Position: Q1 2021 in Review

Winton Group sold out of Cardlytics (CDLX) in Q1 2021, closing a stake of 327 shares — an estimated $467K sold.

Winton Group first reported a position in CDLX in Q3 2019 and held it in 2 quarters. The position peaked at $467K in Q4 2020. 204 funds tracked by Wall St. Rank hold CDLX as of Q1 2021.

Winton Group reported no remaining Cardlytics position as of Q1 2021 after selling out during the quarter.
Winton Group sold 327 Cardlytics shares in Q1 2021, an estimated $467K.
Winton Group first reported a position in Cardlytics in Q3 2019 and held it in 2 quarters.
Winton Group's Cardlytics position peaked at $467K in Q4 2020.
204 funds tracked by Wall St. Rank held Cardlytics as of Q1 2021.

Based on Winton Group's 13F filing for Q1 2021, filed 21 Jul 2021.